Ger­man biotech’s ef­forts to re­vive obe­si­ty tar­get for sol­id tu­mors yield pos­i­tive PhI­Ia re­sults

CatalYm’s sol­id tu­mor can­di­date, which tar­gets a pro­tein pre­vi­ous­ly ex­plored in obe­si­ty, has boost­ed re­spons­es in com­bi­na­tion with an im­mune check­point in­hibitor in an ear­ly-stage tri­al. The re­sults pave the way for the next stage of con­trolled stud­ies in ear­li­er lines of dis­ease.

The Phase IIa GDFA­THER-2 tri­al is eval­u­at­ing the Ger­man biotech’s vi­sugromab plus an im­mune check­point in­hibitor in more than 200 sub­jects with sev­en dif­fer­ent late-line ad­vanced sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER